Inhibitors of enzymes that regulate the stability of the β-catenin destruction complex, and tailored peptides that disrupt the interaction of β-catenin with its transcriptional partners TCF4 and BCL9 in the nucleus are possible points for actions of new pharmaceutical agents and thus possible improvement in cancer treatment [32, 42]. This evidence concerns the gene TCF4 and cancer.